Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric DisordersGlobeNewsWire • 06/30/25
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 06/19/25
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025GlobeNewsWire • 06/18/25
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical ModelsGlobeNewsWire • 06/06/25
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling StudiesGlobeNewsWire • 05/12/25
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury RecoveryGlobeNewsWire • 04/30/25
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/22/24
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024GlobeNewsWire • 11/11/24
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 09/30/24
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net ProfitGlobeNewsWire • 09/19/24
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/04/24
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research CollaborationGlobeNewsWire • 08/27/24